Information Provided By: 
Fly News Breaks for February 28, 2019
AYX
Feb 28, 2019 | 07:06 EDT
JPMorgan analyst Mark Murphy raised his price target for Alteryx to $70 citing last night's "solid" Q4 results and keeps a Neutral rating on the shares. Both the company's revenue and billings were higher than the preliminary results announced on January 24, Murphy tells investors in a post-earnings research note. While the analyst thinks the ASC 606 adoption could increase the volatility of the results, he believes Alteryx's "very solid execution" is fairly valued by the market at current valuation levels.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
